A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma
Weiqin Yang(Chinese University of Hong Kong), Alfred S.L. Cheng(Chinese University of Hong Kong), John Wong(Chinese University of Hong Kong), Otto Ka-Wing Cheung(Chinese University of Hong Kong), Jingying Zhou(Ningbo University Affiliated Hospital), Stephen L. Chan(Chinese University of Hong Kong), Joseph J.�Y. Sung(Nanyang Technological University), Yuan Tian(Duke University), Ka‐Fai To(Chinese University of Hong Kong), Yalin Tu(Chinese University of Hong Kong), Kevin Y. Yip(Chinese University of Hong Kong), Wenshu Tang(Chinese University of Hong Kong), Jing Wang(Shihezi University), Zhiwei Chen(Fujian Medical University), Feng Wu(Nantong University), Yu Feng(Central South University of Forestry and Technology), Jian Cao(Chinese University of Hong Kong), Liangliang Xu(Chinese University of Hong Kong), Zhiwu Tan(Anhui Agricultural University), Anthony W.H. Chan(Chinese University of Hong Kong), Patrick Tan(SingHealth), Hanyong Sun(Shanghai Jiao Tong University), Paul B.S. Lai(Chinese University of Hong Kong)
Cited by 167
Related Papers
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
|The Lancet Infectious Diseases|2020|3.4k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations
|Nature Genetics|2015|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k